...
机译:ObInutuzumab的安全性,药代动力学和药效动活性,一种用于肾移植候选者的候选物脱敏的2型抗CD CD 20单克隆抗体
University of WisconsinMadison Wisconsin;
Cedars‐Sinai Medical CenterLos Angeles California;
Stanford University Medical CenterStanford California;
University of CaliforniaSan Francisco California;
University of Cincinnati College of MedicineCincinnati Ohio;
Johns Hopkins University School of MedicineBaltimore Maryland;
David Geffen School of MedicineLos Angeles California;
University of Cincinnati College of MedicineCincinnati Ohio;
Johns Hopkins University School of MedicineBaltimore Maryland;
Cedars‐Sinai Medical CenterLos Angeles California;
Yale School of MedicineNew Haven Connecticut;
F. Hoffmann‐La RocheBasel Switzerland;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
Genentech Inc.South San Francisco California;
alloantibody; B cell biology; clinical research/practice; clinical trial; immunosuppressant — fusion proteins and monoclonal antibodies: B cell specific; immunosuppression/immune modulation; kidney transplantation/nephrology; pharmacology;
机译:ObInutuzumab的安全性,药代动力学和药效动活性,一种用于肾移植候选者的候选物脱敏的2型抗CD CD 20单克隆抗体
机译:Contrail I学习理由和设计:Iscalimab的药代动力学,药效学,疗效和安全性评估(CFZ533) - De Novo肝移植中的抗CD40单克隆抗体
机译:抗CD40单克隆抗体Iscalimab(CFZ533)的疗效,安全,药代动力学和药效学和药效学(CFZ533)在De Novo肝脏移植受者:我学习的轨迹的理由和设计
机译:在ABO - 不相容的肝移植中预防抗CD20单克隆抗体的使用
机译:通过抗CD19完整单克隆抗体或抗体片段将免疫脂质体阿霉素靶向递送至B淋巴样细胞。
机译:新型II型抗CD20单克隆抗体Obinutuzumab(GA101)的综述用于治疗B细胞恶性肿瘤
机译:新型II型抗CD20单克隆抗体Obinutuzumab(GA101)的综述,用于治疗B细胞恶性肿瘤